The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

Lung cancer is one of the malignant tumors with the highest incidence and mortality in the
world. The overall five-year survival rate of lung cancer is relatively lower than many leading …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …

Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …